FDA grants priority review for Intellia rare genetic disease therapy
Intellia Therapeutics’ experimental gene-editing treatment for a rare genetic disease has received U.S. FDA priority review status, putting the stock back in focus among investors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.